Literature DB >> 7723893

Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni.

R Martinelli1, L J Pereira, E Brito, H Rocha.   

Abstract

To analyze the clinical course and response to therapy 15 patients (9 male and 6 female) with the hepatosplenic form of schistosomiasis mansoni and focal segmental glomerulosclerosis (FSGS) were prospectively studied (mean follow-up = 115.8 +/- 93.2 months). Nephrotic syndrome was the most frequent clinical presentation, followed by abnormalities of urinalysis. The clinical course was progressive: at final evaluation 9 patients (60%) had developed renal failure. Hypertension or/and renal insufficiency at initial evaluation and persistence of the nephrotic syndrome were associated with progression toward advanced renal failure. Response to immunosuppressive therapy was recorded in 30% of the patients; all responsive patients still had normal renal function at final evaluation. The treatment of the Schistosoma mansoni infection did not influence the clinical course of the renal disease. It is concluded that FSGS in patients with hepatosplenic schistosomiasis mansoni is a disease progressing to advanced stage independently of the presence of the parasite.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723893     DOI: 10.1159/000188427

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

Review 1.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

2.  The influence of HIV and schistosomiasis on renal function: a cross-sectional study among children at a hospital in Tanzania.

Authors:  Neema M Kayange; Luke R Smart; Jennifer A Downs; Mwanaisha Maskini; Daniel W Fitzgerald; Robert N Peck
Journal:  PLoS Negl Trop Dis       Date:  2015-01-22

3.  Chapter 9: Infection-related glomerulonephritis.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.